Fei Kang1, Qing Han2, Xiang Zhou1, Zhaohui Zheng2, Shengjun Wang1, Wenhui Ma1, Kui Zhang2, Zhiyong Quan1, Weidong Yang1, Jing Wang3, Ping Zhu4. 1. Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road,, Xi'an, China. 2. Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road,, Xi'an, China. 3. Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road,, Xi'an, China. wangjing@fmmu.edu.cn. 4. Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road,, Xi'an, China. zhuping@fmmu.edu.cn.
Abstract
PURPOSE: To assess the performance of PET vascular activity score (PETVAS) in comparison with SUVmax, inflammatory biomarkers and ITAS-2010 score in a cohort of TAK patients. METHODS: Sixty-four PET/CT scans acquired from 54 TAK patients were analyzed. The inflammatory activity was qualitatively determined by physician's global assessment and quantitatively determined by ITAS-2010 score. SUVmax and PETVAS were acquired by consensus review. Levels of the inflammatory biomarkers C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and pentraxin-3 (PTX-3) were measured. Performance of the qualitative diagnoses and the quantitative correlation were, respectively, compared by receiver operating characteristic (ROC) curve and Spearman correlation coefficient. RESULTS: The biomarkers (CRP, ESR, PTX-3), PET uptake values (SUVmax, PETVAS), and ITAS-2010 scores were all significantly higher in active patients than in non-active ones. The area under the ROC curve and Youden Index of PETVAS and PTX-3 were higher than those of SUVmax, CRP, ESR, and ITAS-2010. PETVAS and PTX-3 resulted in a higher Spearman correlation coefficient with ITAS-2010 than other criteria, either among all patients or within the active group. Alteration trends of PETVAS and PTX-3 during follow-up showed a tighter correlation with clinical progression/remission assessment than other criteria. CONCLUSIONS: In TAK evaluation, PETVAS is superior for qualitative and quantitative assessment, compared with the regional SUVmax. Compared to CRP and ESR, inflammatory biomarker PTX-3 shows better qualitative performance and a higher correlation with PETVAS and ITAS-2010. These findings indicate that the use of PETVAS and PTX-3, instead of SUVmax and CRP/ESR, has potential advantages in the clinical evaluation of TAK.
PURPOSE: To assess the performance of PET vascular activity score (PETVAS) in comparison with SUVmax, inflammatory biomarkers and ITAS-2010 score in a cohort of TAK patients. METHODS: Sixty-four PET/CT scans acquired from 54 TAK patients were analyzed. The inflammatory activity was qualitatively determined by physician's global assessment and quantitatively determined by ITAS-2010 score. SUVmax and PETVAS were acquired by consensus review. Levels of the inflammatory biomarkers C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and pentraxin-3 (PTX-3) were measured. Performance of the qualitative diagnoses and the quantitative correlation were, respectively, compared by receiver operating characteristic (ROC) curve and Spearman correlation coefficient. RESULTS: The biomarkers (CRP, ESR, PTX-3), PET uptake values (SUVmax, PETVAS), and ITAS-2010 scores were all significantly higher in active patients than in non-active ones. The area under the ROC curve and Youden Index of PETVAS and PTX-3 were higher than those of SUVmax, CRP, ESR, and ITAS-2010. PETVAS and PTX-3 resulted in a higher Spearman correlation coefficient with ITAS-2010 than other criteria, either among all patients or within the active group. Alteration trends of PETVAS and PTX-3 during follow-up showed a tighter correlation with clinical progression/remission assessment than other criteria. CONCLUSIONS: In TAK evaluation, PETVAS is superior for qualitative and quantitative assessment, compared with the regional SUVmax. Compared to CRP and ESR, inflammatory biomarker PTX-3 shows better qualitative performance and a higher correlation with PETVAS and ITAS-2010. These findings indicate that the use of PETVAS and PTX-3, instead of SUVmax and CRP/ESR, has potential advantages in the clinical evaluation of TAK.
Authors: Himanshu R Dashora; Joel S Rosenblum; Kaitlin A Quinn; Hugh Alessi; Elaine Novakovich; Babak Saboury; Mark A Ahlman; Peter C Grayson Journal: J Nucl Med Date: 2021-06-04 Impact factor: 10.057
Authors: Benjamin Koa; Austin J Borja; Mahmoud Aly; Sayuri Padmanabhan; Joseph Tran; Vincent Zhang; Chaitanya Rojulpote; Sheila K Pierson; Mark-Avery Tamakloe; Johnson S Khor; Thomas J Werner; David C Fajgenbaum; Abass Alavi; Mona-Elisabeth Revheim Journal: Insights Imaging Date: 2021-03-11